Quinoline derivatives

Details Quinoline derivatives Quinoline derivatives

2002-09-19

2004-09-07

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S159000, C540S575000, C540S599000, C544S060000, C544S128000

Reexamination Certificate

active

06787558

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists, and even more particularly selective neuropeptides Y Y5 receptor antagonists. Accordingly, the compounds of the present invention, their salts and esters can be used in the prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
Neuropetide Y is a 36 amino acid peptide that is widely distributed in the central and peripheral nervous systems. This peptide mediates a number of physiological effects through its various receptor subtypes. Studies in animals have shown that neuropeptide Y is a powerful stimulus of food intake, and it has been demonstrated that activation of neuropeptide Y Y5 receptors results in hyperphagia and decreased thermogenesis. Therefore compounds that antagonise neuropetide Y at the Y5 receptor subtype represent an approach to the treatment of eating disorders such as obesity and hyperphagia.
The current approach is aiming at medical intervention to induce weight loss or prevention of weight gain. This is achieved by interfering with appetite control, which is mediated by the Hypothalamus, an important brain region proven to control food intake. Herein, neuropeptide Y (NPY) has been proven to be one of the strongest central mediators of food intake in several animal species. Increased NPY levels result in profound food intake. Various receptors of neuropeptide Y (NPY) have been described to play a role in appetite control and weight gain. Interference with these receptors is likely to reduce appetite and consequently weight gain. Reduction and long-term maintenance of body weight can also have beneficial consequences on con associated risk factors such as arthritis, cardiovascular diseases, diabetes and renal failure.
SUMMARY OF THE INVENTION
Briefly stated, the present invention relates to the compounds of formula I and their aforementioned salts and esters per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments comprising the said compounds, their pharmaceutically acceptable salts and esters, the use of the said compounds, salts and esters for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders such as hyperphagia and particularly obesity, and the use of the said compounds, salts and esters for the production of medicaments for the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
According to one aspect of the present invention, there is provided a compound of formula I
wherein R
1
, R
2
, R
3
, A
1
and A
2
are as described herewithin.
According to other aspects of the present invention, there is provided a process for making the compounds of formula (I); a method of treating or preventing an illness caused by disorders associated with the NPY receptor comprising administering to a patient in need of such treatment, an effective amount of a compound of the following formula I; and a pharmaceutical composition containing a compound of formula (I) with a pharmaceutically acceptable carrier.


REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 0009123 (2000-02-01), None
patent: WO 01 23389 (2001-04-01), None
patent: WO 02 20488 (2002-03-01), None

Affiliated with

Also associated with

Rating

Quinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3243610